The multiple sclerosis community is buzzing with news of the recent FDA approval of the drug Ocrevus (ocrelizumab) which can be used in the treatment of relapsing-remitting multiple sclerosis (RRMS) and is the first approved drug for the treatment of primary-progressive multiple sclerosis (PPMS).
But how is the drug taken? Here are five important things to know about the dosage and administration of Ocrevus according to everydayhealth.com.
How is it administered?
The first dosage of Ocrevus is delivered via two intravenous infusions, which are taken two weeks apart. Patients will then have further IV infusions every six months.
What is the dosage?
In the clinical trials for the drug, PPMS patients were given 300mg of Ocrevus at each infusion (600mg a month).
Where is it given?
Ocrevus should be given to patients in a clinical setting by a healthcare professional so that patients can be monitored for any adverse reactions.